Palatin Technologies, Inc. (PTN) Fair Value 2026

PTN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.1 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (46/100)

Quick Summary — As of 2026-08-28, Palatin Technologies, Inc. (PTN) trades at $10.48. QOC: 4.1/10. Value Trap Risk: 46/100 (WARN). 0/13 models active.

Key Facts

Ticker
PTN
Price
$10.48
Quality Score
4.1/10
Value Trap Risk
46/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 46 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give PTN?

0 Intrinsic Value Models vs. Current Price ($10.48)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Palatin Technologies, Inc. (PTN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Palatin Technologies, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About PTN?

0 of 13 models are currently active for PTN. See which stocks rank higher →

How Does PTN Rank in Biotechnology?

Among 625 Biotechnology stocks, PTN ranks #528 by Quality of Company score. CirclFi's QOC score of 4.1/10 evaluates 32 fundamental signals. A score of 4.1 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Palatin Technologies, Inc.'s positioning within the Biotechnology segment means that R&D burn rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including gene therapy and cell therapy innovation — shape both the opportunity set and risk profile.

Is PTN a Value Trap?

CirclFi's Value Trap algorithm assigns PTN a score of 46/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Palatin Technologies, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Palatin Technologies, Inc. scores 4.1 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PTN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Palatin Technologies, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

NGENNervGen Pharma Corp.QOC 4.1PDSBPDS Biotechnology CorporationQOC 4.1QNRXQuoin Pharmaceuticals, Ltd.QOC 4.1BIXTBioxytran, Inc.QOC 4.1TENXTenax Therapeutics, Inc.QOC 4.1GNPXGenprex, Inc.QOC 4.1OCGNOcugen, Inc.QOC 6.8LENZLENZ Therapeutics, Inc.QOC 5.5VKTXViking Therapeutics, Inc.QOC 4.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: NGEN · PDSB · QNRX · BIXT · TENX · GNPX · OCGN · LENZ · VKTX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PTN?

6 companies across all industries closest to PTN’s Quality of Company score of 4.1/10.

RDHLRedHill Biopharma Ltd.QOC 4.1BLIVBeLive HoldingsQOC 4.1SOBRSOBR Safe, Inc.QOC 4.1PFSAProfusa, Inc.QOC 4.1CTGLCitrine Global CorpQOC 4.1NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RDHL · BLIV · SOBR · PFSA · CTGL · NVDA

Where Does PTN Sit in CirclFi's Biotechnology Rankings?

PTN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Palatin Technologies, Inc.’s Valuation?

What is Palatin Technologies, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Palatin Technologies, Inc. (PTN). The Quality of Company score is 4.1/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PTN overvalued or undervalued right now?

At $10.48, 0 of 0 active models suggest PTN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Palatin Technologies, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.1 mean for PTN?

Palatin Technologies, Inc.'s QOC of 4.1/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PTN?

CirclFi analyzes PTN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is PTN a value trap in 2026?

Palatin Technologies, Inc.'s Value Trap score is 46/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Palatin Technologies, Inc. (PTN) a Quality of Company score of 4.1/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PTN/ · Methodology
Primary sources for this PTN valuation
  • Financial statements: Palatin Technologies, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000911216) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PTN as of ; valuations recomputed .